Your Health, We Care
Release date: 2026-03-27 16:18:10 Recommended: 3
The use of Anagrelide requires attention to its potential side effects, mitigation methods, and proper storage to ensure therapeutic efficacy and reduce safety risks.
(1) According to clinical study data, the most common adverse reactions to Anagrelide include headache, palpitations, diarrhea, fatigue, edema, nausea, abdominal pain, dizziness, pain, dyspnea, cough, flatulence, vomiting, fever, peripheral edema, rash, chest pain, anorexia, tachycardia, malaise, paresthesia, back pain, pruritus, and dyspepsia.
(2) Among these, headache has the highest incidence rate at 44%, while palpitations and diarrhea account for 26% each.
(1) Anagrelide may cause severe cardiovascular reactions such as QT prolongation, tachycardia, and ventricular fibrillation.
(2) This drug is a PDE3 inhibitor and may cause vasodilation, tachycardia, palpitations, and congestive heart failure.
(3) It should be avoided in patients with known risk factors for QT prolongation.
(1) Clinical monitoring shows that the use of Anagrelide in combination with aspirin increases the risk of major bleeding events.
(2) During treatment, close monitoring for bleeding is required, especially in patients concurrently receiving other medications that may cause bleeding.
(1) Post-marketing reports have identified interstitial lung disease associated with Anagrelide use, including allergic alveolitis, eosinophilic pneumonia, and interstitial pneumonia.
(2) Most cases present as progressive dyspnea with pulmonary infiltrates, with onset ranging from one week to several years after drug administration.
(1) Adverse reactions with an incidence rate between 1% and 5% include flu-like symptoms, chills, arrhythmia, angina pectoris, heart failure, syncope, bleeding, hypertension, and orthostatic hypotension.
(2) Additionally, anemia, thrombocytopenia, elevated liver enzymes, arthralgia, and myalgia may occur.
(1) Anagrelide treatment requires comprehensive clinical monitoring, including complete blood cell count, liver and kidney function assessment, and electrolyte testing.
(2) To prevent thrombocytopenia, platelet counts should be monitored every two days during the first week of treatment, then at least weekly until a maintenance dose is achieved.
(1) The initial dose should be maintained for at least one week before adjusting based on platelet response.
(2) Weekly dose increments should not exceed 0.5 mg/day, with a single dose not exceeding 2.5 mg and a total daily dose not exceeding 10 mg.
(3) Most patients achieve an adequate response at doses between 1.5 and 3.0 mg/day.
(1) For patients with moderate hepatic impairment, treatment should begin at 0.5 mg/day, with frequent monitoring for cardiovascular events.
(2) Elderly and pediatric patients require individualized dose adjustments and close observation of drug responses.
(1) Avoid concomitant use with drugs that may prolong the QT interval, including chloroquine, clarithromycin, haloperidol, methadone, moxifloxacin, amiodarone, disopyramide, procainamide, and pimozide.
(2) Additionally, caution should be exercised when using medications that affect coagulation function.
Anagrelide should be stored at 25°C (77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F), complying with USP controlled room temperature standards.
(1) The medication is packaged in opaque white capsules printed with black "063" identification.
(2) It must be stored in a light-resistant container to prevent direct light exposure, which may affect drug stability.
